Skip to content

The Psychedelics Industry’s Next Hurdle Is How to Go Mainstream

Frozen and ground up psilocybin mushrooms are seen in a Canadian facility.

Frozen and ground up psilocybin mushrooms are seen in a Canadian facility.

Photographer: James MacDonald/Bloomberg
Corrected

Welcome to the latest edition of The Dose. This week, Kristen V. Brown from the health team fills in for Tiffany. She digs into the debate over how to bring psychedelic drugs to the masses. 

The broad category of drugs we have come to call psychedelics are among the most buzzed-about in a very long time. Study results have been breathtaking, showing total symptom alleviation for conditions including post-traumatic stress disorder and depression in huge percentages of patients previously resistant to treatment. Equally astounding are the diverse conditions that these drugs might treat, from addiction and anorexia to migraines.